Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.56 +6.5%	$7.96	$6.10 ▼ $28.67	$556.80M	1.41	399,049 shs	501,623 shs
DNLI Denali Therapeutics	$14.00 -3.6%	$14.24	$10.57 ▼ $33.33	$2.11B	1.33	1.15 million shs	1.31 million shs
INDV Indivior	$16.01 -0.9%	$13.49	$7.33 ▼ $16.34	N/A	0.65	1.24 million shs	1.54 million shs
RXRX Recursion Pharmaceuticals	$5.84 +5.8%	$4.92	$3.79 ▼ $12.36	$2.24B	0.91	17.09 million shs	52.85 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+6.47%	+7.00%	+15.52%	+15.83%	-63.37%
DNLI Denali Therapeutics	-3.65%	-3.58%	-0.64%	+9.89%	-39.16%
INDV Indivior	-0.93%	+3.49%	+15.18%	+77.69%	+48.65%
RXRX Recursion Pharmaceuticals	+5.80%	+10.61%	+14.29%	+6.18%	-30.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.7311 of 5 stars	4.4	2.0	0.0	2.3	4.2	0.6
DNLI Denali Therapeutics	4.5886 of 5 stars	4.5	1.0	4.7	3.2	3.3	0.0
INDV Indivior	0.8493 of 5 stars	1.6	1.0	0.0	0.0	1.7	1.9
RXRX Recursion Pharmaceuticals	1.2923 of 5 stars	2.2	2.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$24.22	182.97% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	140.82% Upside
INDV Indivior	3.25	Buy	$17.00	6.18% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	19.86% Upside

Current Analyst Ratings Breakdown

Latest BCYC, INDV, RXRX, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/30/2025	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	16.80	N/A	N/A	$11.48 per share	0.75
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
INDV Indivior	$1.19B	N/A	$1.80 per share	8.88	($2.52) per share	N/A
RXRX Recursion Pharmaceuticals	$58.84M	40.35	N/A	N/A	$2.61 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	9.36	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest BCYC, INDV, RXRX, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
7/24/2025	Q2 2025	INDV Indivior	$0.25	N/A	N/A	N/A	$239.43 million	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
DNLI Denali Therapeutics	N/A	9.56	9.56
INDV Indivior	N/A	0.88	0.72
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
DNLI Denali Therapeutics	92.92%
INDV Indivior	60.33%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
DNLI Denali Therapeutics	12.50%
INDV Indivior	N/A
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

BCYC, INDV, RXRX, and DNLI Headlines

Recent News About These Companies

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Analysts

July 19 at 2:15 AM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.4% - Here's Why

July 18 at 12:35 PM | marketbeat.com

Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts

July 17 at 6:50 PM | zacks.com

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

July 17 at 12:31 PM | zacks.com

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

July 16 at 11:01 AM | zacks.com

D.A. Davidson & CO. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 11, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

July 10, 2025 | zacks.com

Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating

July 10, 2025 | msn.com

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

July 9, 2025 | insidermonkey.com

Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

July 9, 2025 | marketbeat.com

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

July 9, 2025 | zacks.com

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

July 9, 2025 | finance.yahoo.com

10 Under-the-Radar Tech Stocks With Incredible Growth Potential

July 9, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

July 8, 2025 | insidermonkey.com

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8, 2025 | finanznachrichten.de

Recursion Pharmaceuticals Stock Gains on Plans to Buy Drug-Development Interest from Rallybio

July 8, 2025 | marketwatch.com

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio

July 8, 2025 | in.investing.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher - Should You Buy?

July 8, 2025 | marketbeat.com

Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC

July 8, 2025 | marketbeat.com

10 Stocks Crash Hard Alongside Wall Street

July 8, 2025 | insidermonkey.com

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, INDV, RXRX, and DNLI Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.56 +0.52 (+6.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.31 -0.25 (-2.92%)

As of 07/18/2025 07:04 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Denali Therapeutics NASDAQ:DNLI

$14.00 -0.53 (-3.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.00 -0.01 (-0.04%)

As of 07/18/2025 07:57 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Indivior NASDAQ:INDV

$16.01 -0.15 (-0.93%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$16.01 0.00 (0.00%)

As of 07/18/2025 07:10 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.84 +0.32 (+5.80%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.88 +0.04 (+0.68%)

As of 07/18/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time